Drexel University

Thomas Jefferson University

Oxford University Innovation Ltd

United Therapeutics Corporation

Other

Institute for Hepatitis and Virus Research

Anand Mehta

Timothy Michael Block

Mary Ann Comunale

Raymond A Dwek

Terry D Butters

Frances M Platt

Nicole Zitzmann

Gary S Jacob

Donald H Picker

George W J Fleet

Sandra Carrouee

David Durantel

Baruch S Blumberg

Mengjun Wang

Patrick Robert Romano

Provided are methods, assays, and kits for detecting hepatocellular carcinoma, as well as methods for stratifying subjects among higher and lower risk categories for having hepatocellular carcinoma, and methods of treating and managing treatment of subjects that are suspected or at risk of having hepatocellular carcinoma. Although previous work has attempted to address the need for a highly sensitive, early predictor of hepatocellular carcinoma by assessment of one or more biological factors, none have approached the degree of sensitivity that is required for clinically relevant determination of whether a subject, especially a non-symptomatic subject, has that condition. The present inventors have discovered that certain combinations of factors fulfill this need by conferring a high level of accuracy that was not previously attainable.

Early detection of hepatocellular carcinoma

Methods for diagnosing pathology of the liver in a subject suspected of having such pathology are disclosed. The methods comprise quantifiably detecting lectin binding on proteins in biological fluids, and comparing the detected lectin binding with reference values for the binding of lectin of such proteins in healthy or disease states.

Diagnosis of liver pathology through assessment of protein glycosylation

Methods for diagnosing pathology of the liver in subject suspected of having such pathology by measuring the glycosylation of anti-gal IgG in various biological fluids of the subject.

Diagnosis of liver pathology through assessment of anti-gal IgG glycosylation

Methods for diagnosing pathology of the liver in a subject suspected of having such pathology are disclosed. The methods comprise quantifiably detecting glycosylation, and more specifically fucosylation, on proteins in biological fluids, and comparing the detected glycosylation with reference values for the glycosylation of such proteins in healthy or disease states.

Long chain N-alkyl amino and imino compounds, oxa-substituted derivatives thereof, and pharmaceutical compositions including such compounds are described. The long chain N-alkyl group is a C-Calkyl group. The long chain N-alkyl compounds and oxa-substituted derivatives thereof can be used in the treatment of viral infections, in particular hepatitis B virus or hepatitis C virus, in a cell or an individual. For example, the long chain N-alkyl compounds or oxa-substituted derivatives thereof can be derived from piperidines, pyrrolidines, phenylamines, pyridines, pyrroles, or amino acids.

Long chain N-alkyl compounds and oxa-derivatives thereof

Diagnosis of liver pathology through assesment of protein glycosylation

Long chain n-alkyl compounds and oxa-derivatives thereof

Methods for inhibiting morphogenesis of host cell membrane-budding viruses and infections caused thereby using compounds that inhibit host cell glucosidase or glucosyltransferase enzymes. Methods for treating lipid storage diseases using compounds that inhibit glucosyl transferance enzymes.

Inhibition of membrane-associated viral replication

Growing community of inventors

Lansdale, PA, United States of America

Anand Mehta